Limits...
Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis.

Wu SW, Ma CC, Li WH - Diagn Pathol (2015)

Bottom Line: Subgroup analysis according to sex, tumor location, TNM stage, grade of differentiation and lymph node metastasis were produced.Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were calculated to examine the risk or hazard association, and heterogeneity and publication bias analyses were also performed.With respect to clinicopathological features, there was also no detectable relation between HER-2 expression and sex (OR = 0.91, 95% CI: 0.72-1.15, P = 0.42), tumor location (OR = 1.21, 95% CI = 0.88-1.65, P = 0.24), grade of differentiation (OR = 1.03, 95% CI = 0.72-1.47, P = 0.86), TNM stages (OR = 0.72, 95% CI = 0.31-1.66, P = 0.44), or lymph node metastasis (OR = 1.90, 95% CI = 0.90-4.02, P = 0.09) in CRC.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, The Affiliated Jianhu Hospital of Nantong University, Jianhu People's Hospital, Jianhu, 224700, Jiangsu Province, China.

ABSTRACT

Background: Previous studies have been inconsistent with respect to the reported associations between human epidermal growth factor receptor (HER-2/neu) overexpression in colorectal cancer. The aims of this meta-analysis are to assess its correlation with clinicopathological characteristics and prognostic significance in colorectal cancer.

Methods: Eligible studies were searched in Pubmed, Embase and Web of Science databases. The inclusion criteria were studies that assessed the relationship between HER-2 expression detected by immunohistochemistry (IHC) and the prognosis or clinicopathological features in patients with colorectal cancer (CRC). Subgroup analysis according to sex, tumor location, TNM stage, grade of differentiation and lymph node metastasis were produced. Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were calculated to examine the risk or hazard association, and heterogeneity and publication bias analyses were also performed.

Results: A total of 18 studies comprising 2867 colorectal cancer patients were included to assess the association between HER-2 immunohistochemical expression and clinicopathological characteristics and survival. The overall analysis showed that there was no detectable relation between HER-2 expression and prognosis in colorectal cancer patients with the pooled HR of 1.08 (95% CI: 0.96-1.21, P = 0.21). With respect to clinicopathological features, there was also no detectable relation between HER-2 expression and sex (OR = 0.91, 95% CI: 0.72-1.15, P = 0.42), tumor location (OR = 1.21, 95% CI = 0.88-1.65, P = 0.24), grade of differentiation (OR = 1.03, 95% CI = 0.72-1.47, P = 0.86), TNM stages (OR = 0.72, 95% CI = 0.31-1.66, P = 0.44), or lymph node metastasis (OR = 1.90, 95% CI = 0.90-4.02, P = 0.09) in CRC.

Conclusions: The finding from this present meta-analysis suggested that HER-2 overexpression was not related to clinicopathological characteristics and poor prognostic of colorectal cancer patients.

No MeSH data available.


Related in: MedlinePlus

Flow diagram of studies selection procedure
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4537540&req=5

Fig1: Flow diagram of studies selection procedure

Mentions: A total of 156 articles were identified from a search of the above databases using the search strategy as described above. After exclusion of the trials that were out of the scope of our meta-analysis, 32 studies assessing prognostic value for survival of HER-2 status in patients with colorectal cancer were considered eligible for inclusion in the evaluation. Upon further review, 9 were excluded because it was not possible to allow for the calculation of HR estimate because of insufficient reported data, 5 were excluded because they have overlapped data with other studies. Finally, a total of 18 publications [9–26] were enrolled for the present meta-analysis (Fig. 1).Fig. 1


Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis.

Wu SW, Ma CC, Li WH - Diagn Pathol (2015)

Flow diagram of studies selection procedure
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4537540&req=5

Fig1: Flow diagram of studies selection procedure
Mentions: A total of 156 articles were identified from a search of the above databases using the search strategy as described above. After exclusion of the trials that were out of the scope of our meta-analysis, 32 studies assessing prognostic value for survival of HER-2 status in patients with colorectal cancer were considered eligible for inclusion in the evaluation. Upon further review, 9 were excluded because it was not possible to allow for the calculation of HR estimate because of insufficient reported data, 5 were excluded because they have overlapped data with other studies. Finally, a total of 18 publications [9–26] were enrolled for the present meta-analysis (Fig. 1).Fig. 1

Bottom Line: Subgroup analysis according to sex, tumor location, TNM stage, grade of differentiation and lymph node metastasis were produced.Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were calculated to examine the risk or hazard association, and heterogeneity and publication bias analyses were also performed.With respect to clinicopathological features, there was also no detectable relation between HER-2 expression and sex (OR = 0.91, 95% CI: 0.72-1.15, P = 0.42), tumor location (OR = 1.21, 95% CI = 0.88-1.65, P = 0.24), grade of differentiation (OR = 1.03, 95% CI = 0.72-1.47, P = 0.86), TNM stages (OR = 0.72, 95% CI = 0.31-1.66, P = 0.44), or lymph node metastasis (OR = 1.90, 95% CI = 0.90-4.02, P = 0.09) in CRC.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, The Affiliated Jianhu Hospital of Nantong University, Jianhu People's Hospital, Jianhu, 224700, Jiangsu Province, China.

ABSTRACT

Background: Previous studies have been inconsistent with respect to the reported associations between human epidermal growth factor receptor (HER-2/neu) overexpression in colorectal cancer. The aims of this meta-analysis are to assess its correlation with clinicopathological characteristics and prognostic significance in colorectal cancer.

Methods: Eligible studies were searched in Pubmed, Embase and Web of Science databases. The inclusion criteria were studies that assessed the relationship between HER-2 expression detected by immunohistochemistry (IHC) and the prognosis or clinicopathological features in patients with colorectal cancer (CRC). Subgroup analysis according to sex, tumor location, TNM stage, grade of differentiation and lymph node metastasis were produced. Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were calculated to examine the risk or hazard association, and heterogeneity and publication bias analyses were also performed.

Results: A total of 18 studies comprising 2867 colorectal cancer patients were included to assess the association between HER-2 immunohistochemical expression and clinicopathological characteristics and survival. The overall analysis showed that there was no detectable relation between HER-2 expression and prognosis in colorectal cancer patients with the pooled HR of 1.08 (95% CI: 0.96-1.21, P = 0.21). With respect to clinicopathological features, there was also no detectable relation between HER-2 expression and sex (OR = 0.91, 95% CI: 0.72-1.15, P = 0.42), tumor location (OR = 1.21, 95% CI = 0.88-1.65, P = 0.24), grade of differentiation (OR = 1.03, 95% CI = 0.72-1.47, P = 0.86), TNM stages (OR = 0.72, 95% CI = 0.31-1.66, P = 0.44), or lymph node metastasis (OR = 1.90, 95% CI = 0.90-4.02, P = 0.09) in CRC.

Conclusions: The finding from this present meta-analysis suggested that HER-2 overexpression was not related to clinicopathological characteristics and poor prognostic of colorectal cancer patients.

No MeSH data available.


Related in: MedlinePlus